These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 10810933)

  • 1. Docetaxel (Taxotere) in combination with anthracyclines in the treatment of breast cancer.
    Nabholtz JM; North S; Smylie M; Mackey J; Au HJ; Au R; Morrish D; Salter E; Tonkin K
    Semin Oncol; 2000 Apr; 27(2 Suppl 3):11-8. PubMed ID: 10810933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of the efficacy and safety of docetaxel as monotherapy in metastatic breast cancer.
    Crown J
    Semin Oncol; 1999 Feb; 26(1 Suppl 3):5-9. PubMed ID: 10203264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Docetaxel (Taxotere) plus doxorubicin-based combinations: the evidence of activity in breast cancer.
    Nabholtz JM
    Semin Oncol; 1999 Jun; 26(3 Suppl 9):7-13. PubMed ID: 10426453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-agent docetaxel (Taxotere) in randomized phase III trials.
    Burris HA
    Semin Oncol; 1999 Jun; 26(3 Suppl 9):1-6. PubMed ID: 10426452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review of docetaxel and doxorubicin-based combinations in the management of breast cancer: from metastatic to adjuvant setting.
    Nabholtz JM; Tonkin K; Smylie M; Mackey J; Janowska-Wieczorek A
    Semin Oncol; 1999 Feb; 26(1 Suppl 3):10-6. PubMed ID: 10203265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Compilation of phase I and II trial data of docetaxel and doxorubicin in the treatment of advanced breast cancer and other malignancies.
    Sparano JA
    Semin Oncol; 1998 Dec; 25(6 Suppl 13):10-5. PubMed ID: 9865686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase III studies of single-agent docetaxel in patients with metastatic breast cancer who have progressed despite previous chemotherapy regimens: preliminary results.
    Nabholtz JM; Crown J
    Semin Oncol; 1998 Dec; 25(6 Suppl 13):4-9. PubMed ID: 9865685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Docetaxel (Taxotere) in combination: a step forward.
    Burris HA; Fields S; Peacock N
    Semin Oncol; 1995 Dec; 22(6 Suppl 13):35-40. PubMed ID: 8604452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combining new agents with anthracyclines in metastatic breast cancer: an overview of recent findings.
    Aapro MS
    Semin Oncol; 1999 Feb; 26(1 Suppl 3):17-21. PubMed ID: 10203266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Docetaxel in combination chemotherapy for metastatic breast cancer.
    Khayat D; Antoine E
    Semin Oncol; 1997 Aug; 24(4 Suppl 13):S13-19-S13-26. PubMed ID: 9335513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolution in the treatment of advanced breast cancer.
    Crown J
    Semin Oncol; 1998 Oct; 25(5 Suppl 12):12-7. PubMed ID: 9865706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Docetaxel versus doxorubicin in patients with metastatic breast cancer who have failed alkylating chemotherapy: a preliminary report of the randomized phase III trial. 303 Study Group.
    Aapro M
    Semin Oncol; 1998 Oct; 25(5 Suppl 12):7-11. PubMed ID: 9865705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging role of docetaxel (Taxotere) in the adjuvant therapy of breast cancer.
    Ravdin PM
    Semin Oncol; 1999 Jun; 26(3 Suppl 9):20-3. PubMed ID: 10426455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Doxorubicin and taxane combination regimens for metastatic breast cancer: focus on cardiac effects.
    Valero V; Perez E; Dieras V
    Semin Oncol; 2001 Aug; 28(4 Suppl 12):15-23. PubMed ID: 11552226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Taxoids in combination chemotherapy for metastatic breast cancer.
    Dieras V; Fumoleau P; Bourgeois H; Misset JL; Azli N; Pouillart P
    Anticancer Drugs; 1996 Aug; 7 Suppl 2():47-52. PubMed ID: 8862712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Docetaxel/doxorubicin/cyclophosphamide in the treatment of metastatic breast cancer.
    Nabholtz JM; Smylie M; Mackey JR; Noel D; Paterson AH; al-Tweigeri T; Au D; Sansregret E; Delorme F; Riva A
    Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):37-41. PubMed ID: 9364541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Docetaxel (Taxotere) for the treatment of anthracycline-resistant breast cancer.
    Ravdin PM
    Semin Oncol; 1997 Aug; 24(4 Suppl 10):S10-18-S10-21. PubMed ID: 9275002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Docetaxel (Taxotere): an effective agent in the management of second-line breast cancer.
    van Oosterom AT
    Semin Oncol; 1995 Dec; 22(6 Suppl 13):22-8. PubMed ID: 8604449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Taxoids: effective agents in anthracycline-resistant breast cancer.
    Ravdin PM
    Semin Oncol; 1995 Dec; 22(6 Suppl 13):29-34. PubMed ID: 8604450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of docetaxel (Taxotere) in neoadjuvant chemotherapy of breast cancer.
    Costa SD; von Minckwitz G; Raab G; Blohmer JU; Dresel V; Eidtmann H; Hilfrich J; Jackisch C; Merkle E; Gademann G; Kaufmann M
    Semin Oncol; 1999 Jun; 26(3 Suppl 9):24-31. PubMed ID: 10426456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.